Propanc Biopharma Seeks Spain’s Approval For Foreign Filing License To Submit Two New Patents On Resistant Cancer And Fibrosis Treatments Via Its Australian Subsidiary

Propanc Biopharma, Inc., a biopharmaceutical company focused on developing new treatments for recurrent and metastatic cancer, announced that it has submitted a request for a foreign filing license from Spain for two provisional patents describing new methods for treating resistant cancer and fibrosis. Once approved, the patents will be filed with IP Australia under Propanc Pty Ltd, the company’s wholly owned subsidiary based in Melbourne, Australia. These new discoveries are the result of Propanc’s Joint Research and Drug Discovery program with the Universities of Jaén and Granada in Spain and are expected to be pursued in additional major global markets.

The first provisional patent outlines methods for treating cancers that become resistant to chemotherapy or radiotherapy. Although cancer therapies have improved, mortality rates remain high, and recurrence continues to be a major challenge. Many patients experience treatment failure due to the development of multiple malignancies and resistance to existing therapies, highlighting the need for new and more effective approaches.

The second provisional patent focuses on compositions, methods, applications, and kits for treating fibrosis, particularly organ fibrosis. Fibrosis is characterized by abnormal accumulation of scar tissue caused by excessive deposition of extracellular matrix components. This leads to tissue stiffening, reduced function, and structural damage. Fibrosis can affect nearly any organ system, including the lungs, liver, kidneys, and heart, and is a major contributor to global morbidity and mortality. The condition may develop as a result of chronic inflammation, autoimmune responses, chemical exposure, radiation, or tissue injury. For example, life expectancy following myocardial infarction-related scarring typically ranges from 3 to 8 years for individuals aged 65 to 74, while patients with lung fibrosis commonly have a life expectancy of only 3 to 5 years.

This fibrosis-related patent marks an important milestone for Propanc, as it is the first in the company’s portfolio to describe potential uses of its lead product candidate, PRP, beyond oncology. PRP is a proenzyme therapy designed to influence key biological pathways involved in cancer progression. Some of these pathways, including epithelial-to-mesenchymal transition (EMT), also play a central role in tissue repair and fibrosis, making PRP a promising candidate for broader therapeutic applications.

James Nathanielsz, Chief Executive Officer of Propanc, stated that the submission of both patents represents a significant step forward for the company and expands the commercial possibilities for PRP in treating chronic diseases such as cancer and fibrosis. He noted that Propanc’s planned Phase 1b First-In-Human study in 2026 will determine the therapeutic dose of PRP, enabling the company to advance the therapy into Phase 2 proof-of-concept trials across multiple disease areas. According to Nathanielsz, the company’s goal is to demonstrate PRP’s potential as a novel treatment approach that promotes cellular differentiation and restores more normal cell behavior, without the cytotoxic effects commonly associated with many traditional therapies.